Gentian Diagnostics appoints Torsten Knüttel as VP Reseach & Development

28. Mar 2019 | 2 min read

Moss, 28.03.19

Gentian Diagnostics is pleased to announce the appointment of Mr. Torsten Knüttel as Vice President of Research and Development. Mr. Knüttel will commence in his new position at the latest on the 5th of August 2019. Mr. Knüttel holds a PhD (1999 – 2002) from Leibniz University Hannover in Chemistry/Biotechnology. Since 2013 he has been working for Thermo Fisher Scientific in Oslo, Norway, in the last five years as a Business Development Manager, within the immunodiagnostics/protein biology field. Before joining Thermo Fisher Scientific, Mr. Knüttel worked in GE Healthcare – Medical Diagnostics where he worked for the first 6 years (2004-2010) as a Research Scientist, as a Research & Development Team Leader within regulatory affairs, he then moved into a Technology Transfer Leader role from 2010-2013 within Research & Development and later in GE’s Global Supply Chain.

With the hiring of Mr. Knüttel, we are strengthening our Research and Development department, which will enhance our product development efficiency, while Erling Sundrehagen, Chief Scientific Officer will focus his efforts on our technology innovations and clinical affairs. Commenting on the news, CSO Erling Sundrehagen: “I am delighted to welcome Torsten to the Gentian R&D team. His background and experience fits perfectly with our desire to further enhance our capabilities to develop products that are relevant to our customers. I have known Torsten for several years and I am confident that he is a good contribution to the Gentian organization. I look very much forward to a fruitful and close collaboration with Torsten”.

For further information, please contact

Hilja Ibert CEO, Gentian Diagnostics AS
+47 919 05 242

Njaal Kind CFO, Gentian Diagnostics AS
+47 919 06 525


MeldingsID: 473148


You may also read

Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..